Exact Sciences Launches Oncodetect Test
Exact Sciences has launched Oncodetect, a new test designed to detect molecular residual disease (MRD) across multiple solid tumors, the company announced today. “Exact Sciences is transforming cancer care by…
Tag Archives: Exact Sciences
Exact Sciences Launches Cologuard Plus Test
Exact Sciences has launched Cologuard Plus, a next-generation, noninvasive colorectal cancer screening text, the company announced today. According to a release, the Cologuard Plus test detects 95% of colorectal cancers…
Exact Sciences, Flatiron Health to Partner
Exact Sciences and Flatiron Health, a healthtech company dedicated to improving cancer care and advancing research, are partnering to accelerate clinical evidence generation for Exact Sciences’ molecular residual disease test…
Exact Sciences Presents New Data on MCED Test
Exact Sciences will be sharing results for its multi-cancer early detection (MCED) test at the American Association for Cancer Research (AACR) Special Conference taking place Nov. 13-16 in San Diego,…
Exact Sciences Earns FDA Approval for Cologuard Plus
Exact Sciences announced today that the U.S. Food and Drug Administration (FDA) approved its next-generation multitarget stool DNA test called Cologuard Plus. “Cologuard Plus sets a new performance standard in…
Exact Sciences Gives Report on Blood-Based Test
Exact Sciences announced performance data for its blood-based colorectal cancer (CRC) screening test at the European Society of Medical Oncology (ESMO) Congress, the company announced recently. According to a release,…
Exact Sciences Reports First Patient in Falcon Registry Study
Exact Sciences enrolled its first patient in its Multi-Cancer Early Detection (MCED) Falcon Registry Real-World Evidence Study, the company announced today. According to a release, the study will evaluate the…
Exact Sciences Releases Cologuard Data
Exact Sciences shared new modeling data that shows the impact of the Cologuard tests on patients, healthcare professionals and the U.S. healthcare system since its FDA approval a decade ago,…
Exact Sciences to Collaborate With Mayo Clinic
Exact Sciences is collaborating with the Mayo Clinic to provide comprehensive genomic profiling and hereditary cancer tests to patients, the company announced recently. According to a release, the Mayo Clinic…
Exact Sciences Launches Riskguard Cancer Test
Exact Sciences has launched a hereditary cancer test in the United States called Riskguard, the company announced this week. According to a release, the test provides an individualized patient report…
